PerspectiveDegenerative Retinal Disorders

Rod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling

See allHide authors and affiliations

Science Translational Medicine  07 Apr 2010:
Vol. 2, Issue 26, pp. 26ps16
DOI: 10.1126/scitranslmed.3000866

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The identification of one mechanism that causes vision loss in inherited degenerative retinal disorders revealed a new signaling molecule that represents a potential therapy for these currently untreatable diseases. This protein, called rod-derived cone viability factor (RdCVF), maintains the function and consequently the viability of cone photoreceptor cells in the retina; mice that lack this factor exhibit a progressive loss of photoreceptor cells. The gene encoding RdCVF also encodes, by differential splicing, a second product that has characteristics of a thioredoxin-like enzyme and protects both photoreceptor cells and, more specifically, its interacting protein partner, the tau protein, against oxidative damage. This signaling pathway potentially links environmental insults to an endogenous neuroprotective response.


  • Citation: T. Léveillard, J.-A. Sahel, Rod-derived cone viability factor for treating blinding diseases: From clinic to redox signaling. Sci. Transl. Med. 2, 26ps16 (2010).

View Full Text

Stay Connected to Science Translational Medicine